Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses

@inproceedings{Desel2011RecombinantB,
  title={Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses},
  author={Christiane Desel and Anca Dorhoi and Silke Bandermann and Leander Grode and Bernd Eisele and Stefan H. E. Kaufmann},
  booktitle={The Journal of infectious diseases},
  year={2011}
}
BACKGROUND New vaccines against tuberculosis (TB) are urgently needed because the only available vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), fails to protect against pulmonary TB in adults. The recombinant ΔureC hly+ BCG (rBCG) is more efficient than parental BCG (pBCG) against pulmonary TB in preclinical studies and has proven safe and immunogenic in phase I clinical trials. METHODS In an attempt to identify the mechanisms underlying the superior protection of rBCG, we… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Similar Papers

Loading similar papers…